Clinical trial

Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

NCT02423590

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2014-06-01

PhasePHASE2

Study timeline

Study start (unknown)2014-06-01Date precision: month

Registry last updated2017-08-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Squamous Cell Lung Cancerunresolved

Interventions

Apatorsen (OGX-427)DRUG

GemcitabineDRUG · verified · RxNorm: gemcitabine

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Queen Mary University of Londonlead sponsor

Achieve Life Sciencescollaborator

Mapped research locations

LondonUnited Kingdom4 ManchesterUnited Kingdom1 BirminghamUnited Kingdom1 NottinghamUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02423590 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.